AbbVie Sues HRSA in D.C. District Court Over 340B Patient Definition — Post-Chevron Doctrinal Weapon
AbbVie filed a 72-page complaint April 8 in U.S. District Court for the District of Columbia against HRSA, HHS, Secretary Kennedy, and HRSA Administrator Engels — targeting the 1996 'patient definition' guidance that allows 340B drugs to be dispensed to non-FQHC contract patients. Post-Chevron doctrinal weapon: AbbVie argues HRSA's interpretive guidance lacks force of law.
If successful, would dramatically narrow which patients qualify for 340B savings and gut FQHC contract pharmacy revenue. Joins the pending Maine District Court case (AHA + 4 safety-net hospitals, already vacated rebate model in Feb 2026).
Combined regulatory + litigation pressure on HRSA's 340B authority is the most concentrated industry challenge in program history.
Primary source
AxiosSource packet
This story's primary source + 4 related tracked stories with theirs — one print-ready digest for your team or board packet.
Free — subscribes you to the weekly Intel Brief. Individual sources are always clickable above, no email needed.
FQHC Talent. (2026, April 8). AbbVie Sues HRSA in D.C. District Court Over 340B Patient Definition — Post-Chevron Doctrinal Weapon. Primary source: Axios. Retrieved July 30, 2026, from https://www.fqhctalent.com/intel/abbvie-sues-hrsa-340b-patient-definition-april-2026
More in Risk & Compliance
Jul 16
CMS and CDC reopen the CLIA regulations with a request for information — comments close September 14
Jul 10
Eli Lilly's 340B Termination Turns Into Litigation and Congressional Pushback — Tampa General Sues in Federal Court, 72 House Members Demand HHS Act
Jul 9
OIG declines to sanction an FQHC's produce-box and voucher program — a favorable outcome, but one that legally protects only the health center that asked
Jul 8
$3.3M California Billing-Fraud Settlement Turns on Rendering-Provider NPIs and Uncredentialed NPs/PAs — an Adjacent-Sector Warning FQHCs Should Read Closely